ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Pharmacoepidemiology"

  • Abstract Number: 1515 • ACR Convergence 2023

    Performance of the Revised CRISS in a Phase 3 Trial of Early Systemic Sclerosis

    Dinesh Khanna1, Christopher Denton2, Masataka Kuwana3, Daniel Furst4, Suiyuan Huang1, Barbara White5 and Robert Spiera6, 1University of Michigan, Ann Arbor, MI, 2University College London, London, United Kingdom, 3Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 4University of California Los Angeles, Los Angeles, CA, 5SFJ Pharmaceuticals, Towson, MD, 6Hosptial for Special Surgery, New York, NY

    Background/Purpose: Revised CRISS has been proposed an approvable outcome measure in early diffuse cutaneous SSc (dcSSc)1. The index is undergoing the FDA review as part…
  • Abstract Number: 1582 • ACR Convergence 2023

    Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data

    Bryant England1, Joshua Baker2, Michael George2, Tate Johnson1, Yangyuna Yang1, Punyasha Roul1, Harlan Sayles1, Fang Yu1, Jorge Rojas Jr3, Brian Sauer4, Grant Cannon5, Jeffrey R Curtis6 and Ted R Mikuls7, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3Puget Sound VA and University of Utah, Seattle, WA, 4Salt Lake City VA/University of Utah, Salt Lake City, UT, 5University of Utah and Salt Lake City VA, Salt Lake City, UT, 6Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, 7Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: There is a paucity of data to guide biologic and JAKi DMARD selection in rheumatoid arthritis-interstitial lung disease (RA-ILD), with some reports of higher…
  • Abstract Number: 0136 • ACR Convergence 2023

    The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-term Hydroxychloroquine Use

    Sophie Do, Jennifer Du, Jaejin An, Jim Wang and Antony Lin, Kaiser SCAL, Fontana, CA

    Background/Purpose: Hydroxychloroquine (HCQ) is commonly used for the treatment of various autoimmune diseases. The medication is generally well-tolerated. However, long-term use after 5 years may…
  • Abstract Number: 1620 • ACR Convergence 2023

    Cardiovascular Risk and Fracture Risk Among Women Initiating Treatment with Romosozumab or Denosumab

    Ye Liu1, Tarun Arora2, S. Bobo Tanner3 and Jeffrey Curtis1, 1University of Alabama at Birmingham, Birmingham, AL, 2Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, 3Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Romosozumab (romo) and denosumab (dmab) are recommended for postmenopausal women with osteoporosis (OP) at high risk of fracture. The U.S. prescribing information includes a…
  • Abstract Number: 0147 • ACR Convergence 2023

    Leukotriene Inhibitors Effect on Post-Traumatic Osteoarthritis: A Real-World Evidence Comparative Effectiveness Study

    S. Reza Jafarzadeh1, Matthew Baker2, Christine E. Peloquin3, William H. Robinson4 and David Felson3, 1Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 2Stanford University, Menlo Park, CA, 3Boston University, Boston, MA, 4Stanford University, Palo Alto, CA

    Background/Purpose: Joint injuries frequently lead to post-traumatic osteoarthritis (OA), a disabling condition often affecting young adults, impacting their quality of life and creating substantial economic…
  • Abstract Number: 1692 • ACR Convergence 2023

    Insights on the Use of JAK-inhibitors in Patients with Psoriatic Arthritis in an International Collaboration of Registers (the “JAK-pot” Study)

    Romain Aymon1, Denis Mongin2, Burkhard Leeb3, Monika Mustak-Blagusz4, Jakub Závada5, Karel Pavelka6, Dan Nordstrom7, Nina Trokovic8, Florenzo Iannone9, Catalin Codreanu10, Ziga Rotar11, Tore Kvien12, Sella Provan13, Manuel Enrique Pombo Suarez14, Fernando Alonso15, Fatos Onen16, Nevsun Inanc17, Louis Coupal18, Denis Choquette19, Galina Lukina20, Ori Elkayam21, Victoria Furer21, Ana Maria Rodrigues22, Delphine COURVOISIER23, Axel Finckh24, Michael Nissen2 and Kim Lauper25, 1Geneva University Hospitals, Collonges-sous-Salève, France, 2Geneva University Hospitals, Geneva, Switzerland, 3BioReg, Stockerau, Austria, 4BioReg, Vienna, Austria, 5Institute of Rheumatology, Prague, Czech Republic, 6Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, 7Helsinki University Hospital, Helsinki, Finland, 8University of Helsinki, Helsinki, Finland, 9Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, 10Center for Rheumatic Diseases, Bucharest, Romania, 11University Medical Centre Ljubljana, Ljubljana, Slovenia, 12Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 13Diakonhjemmet Hospital, Oslo, Norway, 14Hospital Cl­ínico Universitario, Santiago de Compostela, Spain, 15Spanish Society of Rheumatology, Madrid, Spain, 16Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, 17Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey, 18Institut de Rhumatologie de Montréal, Montreal, QC, Canada, 19Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, 20Federal state budgetary scientific institution "V.A. Nasonova Research Institute of Rheumatology", Moscow, Russia, 21Tel Aviv Medical Center, Tel Aviv, Israel, 22Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, 23Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, 24HUG, Geneva, Switzerland, 25Geneva University Hospitals, Genève, Switzerland

    Background/Purpose: JAK-inhibitors (JAKi) are increasingly being prescribed to treat various inflammatory conditions, including psoriatic arthritis (PsA). While the understanding of JAKi efficacy and safety in…
  • Abstract Number: 0171 • ACR Convergence 2023

    A Conceptual Framework to Characterize the Indirect Burden of Systemic Lupus Erythematosus (SLE): Findings from Qualitative Patient Interviews

    Vibeke Strand1, Prajakta Masurkar2, Jennifer Reckleff3, Taylor Schwartz4, Alison Silverstein4, Jennifer Osborne4, Josie Lloyd4, Brian Leinwand4, Elaine Karis5, Fatima Barbar-Smiley6 and Karen Costenbader7, 1Stanford University, Portola Valley, CA, 2Amgen, Inc., Atlanta, GA, 3Amgen, Inc., Westlake Village, CA, 4Inovalon Insights, Bowie, MD, 5Amgen, Inc., Colts Neck, NJ, 6Amgen, Inc., Dublin, OH, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: SLE is a chronic autoimmune disorder that affects multiple organs and leads to a variety of symptoms, including joint pain, fatigue, and skin rashes,…
  • Abstract Number: 1812 • ACR Convergence 2023

    Duloxetine and the Risk for Cardiovascular Events in US Veterans with Non-Cancer Pain

    Laura Daniel1, Alyson Dickson2, Puran Nepal1, Otis Wilson3, Adriana Hung2, Dale Plummer3, William Dupont3, Katherine Murray3, C. Michael Stein2, Wayne Ray3 and Cecilia Chung4, 1University of Miami, Nashville, TN, 2Vanderbilt University Medical Center, Nashville, TN, 3Vanderbilt University, Nashville, TN, 4University of Miami, Miami, FL

    Background/Purpose: Duloxetine is a serotonin-norepinephrine reuptake inhibitor approved by the FDA for the treatment of different forms of chronic pain. Because of its adrenergic activity,…
  • Abstract Number: 0247 • ACR Convergence 2023

    Risk of Incident Gout Following Exposure to Recombinant Zoster Vaccine in Adults Aged ≥50 Years in the United States

    Sheryl Kluberg1, Andrew Simon2, Sarah Alam2, Alexander Peters2, Casie Horgan2, Dongdong Li2, Érick Moyneur3, Richard Platt2, Cheryl N McMahill-Walraven4, Djeneba Audrey Djibo4, Qianli Ma5, Mano Selvan5, Claire Pernar6, Najat Ziyadeh6, Aziza Jamal-Allial7, Kimberly Daniels7, O’Mareen Spence8, Driss Oraichi8, Harry Seifert8, Valentine Franck9, Susan Gamble8 and Huifeng Yun8, 1Harvard Medical School and Harvard Pilgrim Health Care Institute, Newton, MA, 2Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, 3StatLog Inc, Quebec City, QC, Canada, 4CVS Health, Blue Bell, PA, 5Humana Healthcare Research, Inc., Louisville, KY, 6Optum, Baltimore, MD, 7Carelon Research, Boston, MA, 8GlaxoSmithKline, Rockville, MD, 9GlaxoSmithKline, Wavre, Belgium

    Background/Purpose: Pre-licensure clinical trials for recombinant zoster vaccine (RZV) identified more frequent gout diagnoses among recipients of RZV than placebo; however, these trials were not…
  • Abstract Number: 1818 • ACR Convergence 2023

    Compliance with Romosozumab and Fracture Risk Among Postmenopausal Women in the U.S

    Ye Liu1, Tarun Arora2, Jeffrey Curtis1 and Jingyi Zhang1, 1University of Alabama at Birmingham, Birmingham, AL, 2Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL

    Background/Purpose: Romosozumab (romo) is a newly approved osteoporosis (OP) medicine for women with postmenopausal OP at high risk of fracture. The utilization pattern of romo…
  • Abstract Number: 0371 • ACR Convergence 2023

    Assessing Methotrexate Adherence in JIA Using Electronic Health Record-Linked Pharmacy Dispensing Data

    Dori Abel1, David Anderson1, Michael Kallan2, Levon Utidjian1, Joyce Chang3, Chen Kenyon1 and Sabrina Gmuca1, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3Boston Children's Hospital, Boston, MA

    Background/Purpose: The extent to which lack of adherence to prescribed treatment regimens contributes to differential disease outcomes in JIA – and demographic disparities in these…
  • Abstract Number: 2008 • ACR Convergence 2023

    Comparative Effectiveness of Denosumab versus Alendronate Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

    Jeffrey Curtis1, Tarun Arora2, Ye Liu1, Tzu-Chieh Lin3, Leslie Spangler3, Vanessa C. Brunetti3, Robert K. Stad3, Michele McDermott3, Brian D. Bradbury3 and Min Kim3, 1University of Alabama at Birmingham, Birmingham, AL, 2Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, 3Amgen, Inc., Thousand Oaks, CA

    Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than oral bisphosphonates, evidence is lacking…
  • Abstract Number: 0435 • ACR Convergence 2023

    Changes in Characteristics of Patients Initiating and Discontinuing Advanced Therapies for Rheumatoid Arthritis Following Release of Safety Data

    Stephanie Song1, Bryant England2, Brian Sauer3, Michael George4, Beth Wallace5, Grant Cannon6, Ted R Mikuls7 and Joshua Baker4, 1Hospital of the University of Pennsylvania, Philadelphia, PA, 2University of Nebraska Medical Center, Omaha, NE, 3Salt Lake City VA/University of Utah, Salt Lake City, UT, 4University of Pennsylvania, Philadelphia, PA, 5Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 6University of Utah and Salt Lake City VA, Salt Lake City, UT, 7Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: The ORAL Surveillance study highlighted risks of cardiac events, thromboembolism (VTE), and cancer associated with Janus kinase inhibitors (JAKi). The aim of this study…
  • Abstract Number: 2137 • ACR Convergence 2023

    Line of Therapy of Biologics and JAK Inhibitors in RA, PsA and AxSpA: Implications for Design and Uptake of New Drugs and Diagnostics

    Jeffrey Curtis1, Fenglong Xie1, Yuji Su2, Patrick Stewart3 and Amy S. Mudano1, 1Illumination Health, Hoover, AL, 2University of Alabama at Birmingham and Illumination Health, Birmingham, AL, 3Illumination Health, Birmingham, AL

    Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA) have an increasing array of treatment options available, and new blood-based diagnostic…
  • Abstract Number: 0469 • ACR Convergence 2023

    Hydroxychloroquine and Preeclampsia Risk in Lupus Pregnancy: Results from a Large Regional Integrated Health Network

    Julia Simard1, Emily Liu2, Amadeia Rector3, Miranda Cantu4, Daniel Kuo5, Eliza Chakravarty6, Maurice Druzin7, Gary Shaw7, Michael Weisman8 and Monique Hedderson2, 1Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, 2Kaiser Permanente Division of Research, Oakland, CA, 3Stanford University, San Francisco, CA, 4Global Lupus Support Group, Portage, MI, 5Kaiser Permanente, Redwood City, CA, 6Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Stanford University, Stanford, CA, 8Stanford, Los Angeles, CA

    Background/Purpose: Pregnancies in patients with systemic lupus erythematosus (SLE) are at greater risk of preeclampsia. Hydroxychloroquine (HCQ) is recommended during SLE pregnancy to control disease…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology